Replies to post #198008 on Biotech Values

[ciotera]

Re: Venetoclax

Funny, how they are reporting ORR and PR but not CR.
10% CR is a failure. Imbruvica probably has that much. So, it's a success as far as it's approvable based on this study, but how will it compete against Imbruvica?